Total Funding
22
Total FundingSeries A raised
Growth Score
pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
70635
CerSci Therapeutics is poised to deliver a new generation of non-opioid medicines to treat acute and chronic pain.
- Marco Pappagallo: Chief Medical Officer
Scott Dax: Chief Science OfficerPast Role: Galleon Pharmaceuticals, Chief Technology Officer & Vice President-Chemistry
About the Company
CerSci Therapeutics, a non-opioid drug development firm based in Dallas, Texas, has received approval of their Investigational New Drug (IND) application for CT-044 from the United States Food and Drug Administration (FDA) indicating that its Phase I safety and tolerability clinical trial may proceed (commence phase I dosing June 2019). CT-044, a
non-metal based, orally bioavailable, small molecule Radical Species Decomposition Accelerant (RSDAx) of peroxynitrite and hydrogen peroxide, is proposed for the treatment of acute and chronic pain, including acute post-surgical pain and painful diabetic neuropathy.
Hispanic / Latine Founded
Hispanic / Latine Led
